Treatment of neurological and mental disorders

• US 5,470,846 A
• Filed: 01/14/1994
• Issued: 11/28/1995
• Est. Priority Date: 01/14/1994
• Status: Expired due to Fees

• Current Assignee: Sandyk, Reuven
• Original Assignee: Sandyk, Reuven
• Inventors: Sandyk, Reuven
• Primary Examiner(s): Raymond, Richard L.
• Assistant Examiner(s): TILL, MARY C
• Application Number:
  US08/181,677
• Time in Patent Office: 683 Days
• Field of Search: 514/159, 514/160, 514/250, 514/355, 514/345, 514/654, 514/419, 514/657
• US Class Current: 514/159
• CPC Class Codes: A61K 31/122 having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61K 31/375 Ascorbic acid, i.e. vitamin C; Salts thereof
• CPC Class Codes: A61K 31/4015 having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• CPC Class Codes: A61K 31/405 Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
• CPC Class Codes: A61K 31/4188 condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
• CPC Class Codes: A61K 31/4415 Pyridoxine, i.e. Vitamin B6 pyridoxal phosphate A61K31/675
• CPC Class Codes: A61K 31/48 Ergoline derivatives, e.g. lysergic acid, ergotamine
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61K 31/506 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61K 31/51 Thiamines, e.g. vitamin B1
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 31/7076 containing purines, e.g. adenosine, adenylic acid
• CPC Class Codes: A61K 33/06 Aluminium, calcium or magnesium; Compounds thereof , e.g. clay
• CPC Class Codes: A61N 2/002 in combination with another treatment
• CPC Class Codes: A61N 2/006 for magnetic stimulation of nerve tissue
• CPC Class Codes: A61N 2/02 using magnetic fields produced by coils, including single turn loops or electromagnets A61N2/12 takes precedence

Abstract

A method of treating neurological and mental disorders which are associated with and/or related pathogenetically to deficient serotonin neurotransmission and impaired pineal melatonin functions in humans is described which comprises administering to a human in need thereof an effective amount of a composition which increases serotonin transmission to the patient to be treated followed by the application to the brain of the patient of a sufficient amount of an AC pulsed magnetic field of proper intensity and frequency to treat the disorder.

Claims

1. A method of treating neurological and mental disorders which are associated with and related pathogenetically to deficient serotonin neurotransmission and impaired pineal melatonin functions in humans and for treating neurological and mental disorders which are associated with or related pathogenetically to deficient serotonin neurotransmission and impaired pineal melatonin functions in humans, which comprises administering to a human in need thereof an effective amount of a composition which increases serotonin transmission to the patient to be treated followed by the application to the brain of the patient of a sufficient amount of AC pulsed magnetic field of proper intensity and frequency to treat the disorder.

2. A method according to claim 1 wherein the AC pulsed magnetic field is applied to the brain of the patient in two applications, an initial application followed by an interval of time and then the second pulse application.

3. A method according to claim 1 wherein said composition comprises an effective amount of one or more of the following:

an effective amount of a serotonin precursor, an effective amount of a stimulant to increase plasma tryptophan concentrations, a sufficient amount of a stimulant to facilitate the transport of tryptophan into the brain of the human, an effective amount of a stimulant of serotonin synthesis, an effective amount of a serotonin re-uptake inhibitor, an effective amount of a stimulant of serotonin release and an effective amount of a stimulant of serotonin receptors.

4. A method according to claim 3 wherein the composition includes the serotonin precursor which is L-tryptophan or L-5-hydroxytryptophan.

5. A method according to claim 3 wherein the composition includes the stimulant to increase plasma tryptophan concentration which is a salicylate.

6. A method according to claim 3 wherein the composition includes the stimulant to facilitate the transport of tryptophan into the brain which is vitamin B₃, chromium or a mixture thereof.

7. A method according to claim 3 wherein the composition includes the stimulant of serotonin synthesis which is vitamin B₁, vitamin B₃, vitamin B₆, biotin, S-adenosylmethionine, folic acid, ascorbic acid, magnesium, or mixtures of two or more thereof.

8. A method according to claim 3 wherein the composition includes the serotonin re-uptake inhibitor which is sertraline, trazodone or a mixture thereof.

9. A method according to claim 3 wherein the composition includes the stimulant of serotonin release which is fenfluramine.

10. A method according to claim 3 wherein the composition includes the stimulant of serotonin receptors which is an ergoloid mesylate and pergolide mesylate.

11. A method according to claim 1 wherein the intensity of the AC pulsed magnetic field is in the range of 7.5 to 75 picotesla over the patient'"'"'s scalp.

12. A method according to claim 2 wherein the duration of the first AC pulsed magnetic field is 15-20 minutes.

13. A method according to claim 1 wherein the AC pulsed magnetic field is a time varying field with a waveform which is sinusoidal, triangular, trapezoidal, square or a composite thereof, dependent upon the condition to be treated.

14. A method according to claim 1 for the treatment of multiple sclerosis wherein the AC frequency is 2-5 Hz.

15. A method according to claim 1 for the treatment of Parkinson'"'"'s disease, Alzheimer'"'"'s disease, migraine, dystonia, tardive dyskinesia, depression, and schizophrenia wherein the AC frequency is 5-8 Hz.

16. A method according to claim 2 for the treatment of seizure disorders wherein the AC frequency for the first pulse is 4-5 Hz, and the AC frequency for the second pulse is 5-7 Hz.

17. A method according to claim 2 wherein the time delay between the application of the first AC pulse and the second AC pulse is 15-45 minutes.

18. A method according to claim 2 wherein the duration of the first AC pulse is in the range of 15-20 minutes and the duration of the second AC pulse is within the range of 15-45 minutes.

19. A method according to claim 1 wherein the patient'"'"'s eyes are shielded during the application of each AC pulse.

20. A method according to claim 3 wherein the composition is administered beginning four to eight weeks before the application of the AC pulse.

21. A method according to claim 20 wherein the components of the composition are administered to the patient beginning four to eight weeks prior to the application of the first AC pulse.

22. A method according to claim 21 wherein the components are administered six to eight weeks prior to the application of the first AC pulse.

23. A method according to claim 1 wherein the field starts with a given direction and then reverses direction during each cycle.

24. A method according to claim 1 wherein the fields are applied to the patient'"'"'s head using a helmet-like transducer array.

25. A method according to claim 1 wherein the fields have lines of force normal to the array.

26. A method according to claim 24 wherein the helmet-like transducer array comprises an array of coils comprising four rows of four coils.

27. A method according to claim 24 wherein the helmet-like transducer array comprises an array of coils comprising four rows of six coils.